Скачать презентацию Infective Endocarditis Senior Oral Medicine Chapter 2 August Скачать презентацию Infective Endocarditis Senior Oral Medicine Chapter 2 August

BB.SOMch2.10.ppt

  • Количество слайдов: 16

Infective Endocarditis Senior Oral Medicine Chapter 2 August 27, 2009 Susan Settle, D. D. Infective Endocarditis Senior Oral Medicine Chapter 2 August 27, 2009 Susan Settle, D. D. S.

Infective Endocarditis • A microbial infection of the endothelial surface of the heart or Infective Endocarditis • A microbial infection of the endothelial surface of the heart or valves • Usually is near congenital or acquired cardiac defects • Designated by the causative organism • Also classified as NVE or PVE

Etiology • Streptococci most common cause (35 -60%) – Mostly viridans group • Staphylococci Etiology • Streptococci most common cause (35 -60%) – Mostly viridans group • Staphylococci about 30 -40 and gaining – S. aureus most common cause in IVDU’s – Incidence increasing in hospital-acquired infections

Epidemiology • Population Groups At Greater Risk: – Rheumatic Fever History – Hemodialysis – Epidemiology • Population Groups At Greater Risk: – Rheumatic Fever History – Hemodialysis – Previous History Of Endocarditis – Patients With Prosthetic Valves – IV Drug Users (30% Risk Within 2 Years)

Predisposing Conditions • • • Mitral valve prolapse Aortic valve disease Congenital heart disease Predisposing Conditions • • • Mitral valve prolapse Aortic valve disease Congenital heart disease Prosthetic valve Intravenous drug use No identifiable cause in 25 -47%

Epidemiology • • More Common In Median Age 50 Years Acute Cases Increasing Streptococcal Epidemiology • • More Common In Median Age 50 Years Acute Cases Increasing Streptococcal Cases Slightly; Fungal And Gram Negative Cases Increasing

Epidemiology • Incidence Increases With Age, Probably Due To Increased Cardiac Disease And Decreased Epidemiology • Incidence Increases With Age, Probably Due To Increased Cardiac Disease And Decreased Immunity • Prosthetic Heart Valve Infections Are Increasing

Epidemiology • Mitral Valve Prolapse: Only 1/4 Of MVP Patients Have Mitral Insufficiency (Regurgitation Epidemiology • Mitral Valve Prolapse: Only 1/4 Of MVP Patients Have Mitral Insufficiency (Regurgitation Or Murmur) - This Results In The Very Slight Increased Risk For Endocarditis

3 Types Of Endocarditis Lesions • Cardiac Lesions • Embolic Lesions: Friable Cardiac Lesions 3 Types Of Endocarditis Lesions • Cardiac Lesions • Embolic Lesions: Friable Cardiac Lesions That Break Away • General Lesions

Cardiac Lesions Usually Valvular Most Often Mitral Valve May Cover The Entire Valve Mass Cardiac Lesions Usually Valvular Most Often Mitral Valve May Cover The Entire Valve Mass Of Platelets, Fibrin And Bacteria • Sterile Vegetations May Occur In 50% Of Lupus Patients • •

General Lesions • • Enlarged Spleen Arthritis Clubbing Of Fingers Cardiac Failure Conduction Abnormalities General Lesions • • Enlarged Spleen Arthritis Clubbing Of Fingers Cardiac Failure Conduction Abnormalities Stroke Psychiatric Disease Renal Failure

Mortality • Overall Rate About 40% • Death Usually Due To Heart Failure Resulting Mortality • Overall Rate About 40% • Death Usually Due To Heart Failure Resulting From Valve Dysfunction • Highest Death Rate Is In Early Prosthetic Valve Endocarditis

Major Diagnostic Criteria • Positive Blood Culture • Echocardiogram Findings Of Endocardial Involvement • Major Diagnostic Criteria • Positive Blood Culture • Echocardiogram Findings Of Endocardial Involvement • New Valvular Regurgitation

Minor Diagnostic Criteria • • Predisposing Heart Conditions IV Drug Use Vascular Emboli Osler Minor Diagnostic Criteria • • Predisposing Heart Conditions IV Drug Use Vascular Emboli Osler Nodes Aneurysm Roth Spots Of The Eye Splinter Hemorrhages

Treatment • Treat It Early! • Culture • Use Bactericidal Agents – PCN G; Treatment • Treat It Early! • Culture • Use Bactericidal Agents – PCN G; Cefatriaxone; PCN G + Gentamicin; Nafcillin; Vancomycin

Treatment • Use Adequate Dosage • Parenteral Route • Sufficient Duration: 4 -6 Weeks Treatment • Use Adequate Dosage • Parenteral Route • Sufficient Duration: 4 -6 Weeks Or Longer